

**Table 2 Patient characteristics and treatment outcomes in the group treated with interferon and ribavirin according to hepatitis C virus genotype**

Pretreatment variable	Genotype 1 (n = 46)		Genotype 4 (n = 150)		Genotypes 2/3 (n = 46)		P-value
<i>Age [mean (SD) years]</i>	45.9	(9.1)	46.5	(8.4)	45.3	(10.8)	0.73
<i>Sex (male) (no. %)</i>	35	76.1	129	86.0	32	69.6	0.05
<i>BMI (no. %)</i>							0.36
Normal	17	18.1	43	45.7	34	36.2	
Overweight/obese	29	19.6	75	50.7	44	29.7	
<i>Laboratory parameters</i>							
High fibrosis score (F3,F4) (no. %)	17/38	44.7	51/137	37.2	10/39	25.6	0.11
ALT level [mean (SD)] (IU/mL)	83.2	(67.0)	100.0	(82.2)	98.3	(81.8)	1.00
ALT quotient* [mean (SD)]	2.1	(1.7)	2.5	(1.6)	2.4	(2.7)	0.98
Albumin level [mean (SD)] (g/L)	41.6	(4.1)	42.0	(2.4)	42.7	(9.4)	0.49
Platelet count [mean (SD)] (× 10 <sup>9</sup> /L)	212.1	(94.4)	186.7	(62.0)	212.1	(79.7)	0.77
Pretreatment viral load [mean (SD)] (× 10 <sup>3</sup> IU/mL)	475.1	(201.2)	437.4	(213.5)	526.1	(200.7)	0.95
<i>Treatment</i>							
Naïve to treatment (no. %)	39	84.8	132	88.0	41	89.1	0.27
Peg-IFN α-2a treatment (no. %)	38	82.6	135	90.0	40	87.0	0.14
<i>Outcome (no. %)</i>							
End-of-treatment virological response	22/46	47.8	89/150	59.3	39/46	84.7	0.002
Sustained virological response	21/46	45.6	75/147	51.0	34/43	79.1	0.002

\*ALT/40, i.e. the upper limit of normal.

BMI = body mass index; SD = standard deviation; ALT = alanine aminotransferase. Peg-IFN α-2a = pegylated interferon alpha 2a.